Terns Pharmaceuticals shares are trading higher after the company announced that it will present preclinical data supporting TERN-501 in combination with a GLP-1 receptor agonist for obesity at the American Diabetes Association 84th Scientific Sessions.
Portfolio Pulse from Benzinga Newsdesk
Terns Pharmaceuticals shares are trading higher following the announcement that the company will present preclinical data on TERN-501 in combination with a GLP-1 receptor agonist for obesity at the American Diabetes Association 84th Scientific Sessions.
June 24, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharmaceuticals shares are trading higher after the company announced it will present preclinical data on TERN-501 in combination with a GLP-1 receptor agonist for obesity at the ADA 84th Scientific Sessions.
The announcement of presenting preclinical data at a major scientific conference is a positive development, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100